European Heart Journal Advance Access originally published online on June 3, 2008
European Heart Journal 2008 29(15):1922; doi:10.1093/eurheartj/ehn244
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org
Possible involvement of advanced glycation end products in carry-over benefits of atorvastatin in ASCOT-BPLA
Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications
Kurume University School of Medicine
67 Asahi-machi Kurume 830-0011
Japan
Tel: +81 942 31 7873
Fax: +81 942 31 7873
Email: shoichi@med.kurume-u.ac.jp
| The first 10% of the full text of this article appears below. |
I read with interest the recent study by Sever et al.,1 which reported that patients originally assigned atorvastatin continued to demonstrate lower event rates in most cardiovascular endpoints after the termination of Lipid Lowering Arm of the ASCOT (ASCOT-LLA)